

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CSPC PHARMACEUTICAL GROUP LIMITED,
CSPC OUYI PHARMACEUTICAL CO., LTD.,
CONJUPRO BIOTHERAPEUTICS, INC., and APOTEX INC.,

Petitioners,

v.

IPSEN BIOPHARM LTD.,

Patent Owner.

Case No. IPR2025-00505¹
U.S. Patent No. 11,344,552

PATENT OWNER'S REQUEST FOR ORAL ARGUMENT

¹ Apotex Inc., which filed a petition in IPR2025-01531, has been joined as a petitioner in this proceeding.

Pursuant to 37 C.F.R. § 42.70(a) and the Board's Scheduling Order (Paper 14) entered on August 14, 2025, Patent Owner Ipsen Biopharm Ltd. ("Ipsen") hereby respectfully requests oral argument in this proceeding at the United States Patent and Trademark Office Headquarters in Alexandria, Virginia. The oral hearing is currently scheduled for May 19, 2026. Paper 14 at 12. Ipsen requests that the Board allot 120 minutes total for the oral argument, which would be divided equally between Patent Owner and Petitioners (up to 60 minutes per side). Ipsen would prefer an in-person hearing, assuming that is convenient for the Board. Petitioners have indicated that they agree with these proposed time limits for the oral argument.

Ipsen also requests the ability to use audio/visual equipment to present demonstratives and exhibits during the oral hearing, to the extent such equipment is available at the time of the hearing.

The issues to be argued include:

1. The patentability of Claims 1-15 of U.S. Patent No. 11,344,552;
2. Any other issues the Patent Owner and Petitioners properly raised in the Petition, Patent Owner Response, Reply, and Sur-Reply in the proceeding;
3. Any procedural or evidentiary issues raised in such briefing; and

4. Any other issues that the Board deems necessary for issuing a Final Written Decision.

Date: April 6, 2026

By: *James M. Glass*

James M. Glass (Reg. No. 46,729)
QUINN EMANUEL URQUHART &
SULLIVAN LLP
295 5th Ave., 9th Floor
New York, NY 10016
Email: jimglass@quinnemanuel.com
Phone: 212-849-7142
Fax: 212-849-7100

*Counsel for Patent Owner
Ipsen Biopharm Ltd.*

CERTIFICATE OF SERVICE (37 C.F.R. §§ 42.6(E), 42.105(A))

The undersigned hereby certifies that on April 6, 2026 copies of the foregoing document was served upon the following parties via electronic mail, with a copy to ipdocket@foxrothschild.com (referencing Attorney Docket No. 340008.00021):

Lead Counsel:

Luke Toft (Reg. No. 75,311)
ltoft@foxrothschild.com
Fox Rothschild LLP
33 South 6th Street, Suite 3600
Minneapolis, MN 55402
Tel: (612) 607-7336
Fax: (612) 607-7100

Backup Counsel:

Joe Chen (Reg. No. 70,066)
joechen@foxrothschild.com
Fox Rothschild LLP
212 Carnegie Center, Suite 400
Princeton, NJ 08540
Tel: (609) 844-3024
Fax: (609) 896-1469

Howard S. Suh (pro hac vice to be filed)
hsuh@foxrothschild.com
Fox Rothschild LLP
101 Park Avenue, 17th Floor
New York, NY 10178
Tel: (212) 878-7914
Fax: (212) 692-0940

Date: April 6, 2026

By: James M. Glass

James M. Glass (Reg. No. 46,729)
QUINN EMANUEL URQUHART &
SULLIVAN LLP
295 5th Ave., 9th Floor
New York, NY 10016
Email: jimglass@quinnemanuel.com
Phone: 212-849-7142
Fax: 212-849-7100

*Counsel for Patent Owner
Ipsen Biopharm Ltd.*